HCPLive Network

Drug Reduces Brain Lesions in Multiple Sclerosis

Tuesday, April 17 (HealthDay News) -- As part of a Phase 2 trial, Timothy Vollmer, M.D., from the University of Colorado in Denver, and colleagues randomly assigned 407 patients with relapsing-remitting MS to placebo or one of three doses of ONO-4641 (0.05 mg, 0.10 mg, or 0.15 mg) once a day for 26 weeks. Participants were aged 18 to 55 years and had Expanded Disability Status Scale scores up to 5.5.

Based on brain scans performed every four weeks starting at week 10, the researchers found that, compared with placebo, there was a reduction in gadolinium-enhancing lesions of 82 percent for the 0.05 mg dose, 92 percent for the 0.10 mg dose, and 77 percent for the 0.15 mg dose. Adverse events appeared to be dose related and included cardiovascular events, liver enzyme elevations, and grade 4 lymphopenia.

"ONO-4641 demonstrated statistically significant efficacy on key end points, compared to placebo, and was well tolerated in patients with relapsing-remitting MS," Vollmer and colleagues conclude.

The study was supported by Ono Pharmaceutical Co., Ltd., which developed ONO-4641.

Press Release
More Information

An experimental drug, ONO-4641, which is an oral sphingosine-1-phosphate receptor agonist, reduces the number of brain lesions in patients with relapsing-remitting multiple sclerosis, according to a study presented at the annual meeting of the American Academy of Neurology, held from April 21 to 28 in New Orleans.

Copyright © 2012 HealthDay. All rights reserved.

Further Reading
Results from the CLARITY study show cladribine reduces the relapse rate in multiple sclerosis patients who have failed other disease-modifying therapies.
Three recent studies looked at the link between vitamin D and MS, the link between heat and the brains of patients with MS, and a cure for MS.
Patients treated with ofatumumab, an anti-B cell antibody, for 24 weeks showed a significant reduction in disease activity, as measured by the appearance of new brain lesions.
Study data from two phase 3 clinical trials announced at AAN 2014 show sustained effects one year after two years of treatment with alemtuzumab in patient with MS.
Mindfulness meditation can improve fatigue, depression, and other measure of quality of life in patietns with multiple sclerosis.
Study results show that oral laquinimod reduces the annual relapse rate in patients with relapsing-remitting multiple sclerosis.
Study finds no improvement in cognitive impairment among patients with multiple sclerosis treated with ginkgo biloba extract.
More Reading